Cargando…

Preclinical Comparison of Stem Cells Secretome and Levodopa Application in a 6-Hydroxydopamine Rat Model of Parkinson’s Disease

Parkinson’s Disease (PD) is characterized by the massive loss of dopaminergic neurons, leading to the appearance of several motor impairments. Current pharmacological treatments, such as the use of levodopa, are yet unable to cure the disease. Therefore, there is a need for novel strategies, particu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teixeira, Fábio G., Vilaça-Faria, Helena, Domingues, Ana V., Campos, Jonas, Salgado, António J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072263/ https://www.ncbi.nlm.nih.gov/pubmed/32012897 http://dx.doi.org/10.3390/cells9020315

Ejemplares similares

Long-term Levodopa Treatment Accelerates the Circadian Rhythm Dysfunction in a 6-hydroxydopamine Rat Model of Parkinson's Disease
por: Li, Si-Yue, et al.
Publicado: (2017)

Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson’s Disease
por: Barata-Antunes, Sandra, et al.
Publicado: (2020)

Mesenchymal Stem Cells-derived Exosomes: A New Possible Therapeutic Strategy for Parkinson’s Disease?
por: Vilaça-Faria, Helena, et al.
Publicado: (2019)

Amphiregulin blockade decreases the levodopa‐induced dyskinesia in a 6‐hydroxydopamine Parkinson's disease mouse model
por: Kambey, Piniel Alphayo, et al.
Publicado: (2023)

Mitochondrial Dynamics and Mitophagy in the 6-Hydroxydopamine Preclinical Model of Parkinson's Disease
por: Galindo, Maria F., et al.
Publicado: (2012)

Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats
por: Zhang, SuFang, et al.
Publicado: (2014)

The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
por: Wu, Na, et al.
Publicado: (2018)

Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa–Induced Dyskinesia via Lower β-Arrestin2 in 6-Hydroxydopamine Parkinson’s Rats
por: Wang, Wen-Wen, et al.
Publicado: (2019)

Secretome released from hydrogel-embedded adipose mesenchymal stem cells protects against the Parkinson’s disease related toxin 6-hydroxydopamine
por: Chierchia, Armando, et al.
Publicado: (2017)

5-HT(1A) receptor activation improves anti-cataleptic effects of levodopa in 6-hydroxydopamine-lesioned rats
por: Mahmoudi, J., et al.
Publicado: (2011)

6‐Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata
por: Vegas‐Suárez, Sergio, et al.
Publicado: (2020)

Paeonol Protection Against Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson’s Disease
por: Ghalami, Jamileh, et al.
Publicado: (2021)

Effect of Levodopa on Reward and Impulsivity in a Rat Model of Parkinson’s Disease
por: Carvalho, Miguel M., et al.
Publicado: (2017)

Carnosic Acid Alleviates Levodopa-Induced Dyskinesia and Cell Death in 6-Hydroxydopamine-lesioned Rats and in SH-SY5Y Cells
por: Lai, Chun-Yi, et al.
Publicado: (2021)

Bone Marrow Mesenchymal Stem Cells' Secretome Exerts Neuroprotective Effects in a Parkinson's Disease Rat Model
por: Mendes-Pinheiro, Bárbara, et al.
Publicado: (2019)

Mesenchymal stem cells secretome: current trends and future challenges
por: Teixeira, Fábio G., et al.
Publicado: (2019)

Intranasal delivery of mitochondria for treatment of Parkinson’s Disease model rats lesioned with 6-hydroxydopamine
por: Chang, Jui-Chih, et al.
Publicado: (2021)

Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson's Disease
por: Teixeira, Fábio G., et al.
Publicado: (2016)

Alterations of BDNF and trkB mRNA Expression in the 6-Hydroxydopamine-Induced Model of Preclinical Stages of Parkinson’s Disease: An Influence of Chronic Pramipexole in Rats
por: Berghauzen-Maciejewska, Klemencja, et al.
Publicado: (2015)

N-Acetylcysteine Treatment May Compensate Motor Impairments through Dopaminergic Transmission Modulation in a Striatal 6-Hydroxydopamine Parkinson’s Disease Rat Model
por: Caridade-Silva, Rita, et al.
Publicado: (2023)

Cognitive-Enhancing Effect of Quercetin in a Rat Model of Parkinson's Disease Induced by 6-Hydroxydopamine
por: Sriraksa, Napatr, et al.
Publicado: (2012)

Treadmill exercise alleviates short-term memory impairment in 6-hydroxydopamine-induced Parkinson’s rats
por: Cho, Han-Sam, et al.
Publicado: (2013)

Impaired Voluntary Wheel Running Behavior in the Unilateral 6-Hydroxydopamine Rat Model of Parkinson's Disease
por: Pan, Qi, et al.
Publicado: (2015)

Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson’s disease
por: Westphal, Robert, et al.
Publicado: (2017)

Transcriptome profiling of five brain regions in a 6‐hydroxydopamine rat model of Parkinson’s disease
por: Lyu, Ying, et al.
Publicado: (2021)

Changes in the Neuronal Architecture of the Hippocampus in a 6-Hydroxydopamine-Lesioned Rat Model of Parkinson Disease
por: Kim, Bohye, et al.
Publicado: (2022)

Parkinson’s Disease and the Heart: Studying Cardiac Metabolism in the 6-Hydroxydopamine Model
por: Silva da Fonsêca, Victor, et al.
Publicado: (2023)

Secretome of Undifferentiated Neural Progenitor Cells Induces Histological and Motor Improvements in a Rat Model of Parkinson's Disease
por: Mendes‐Pinheiro, Bárbara, et al.
Publicado: (2018)

Neuroprotective Effect of Pseudoginsenoside-F11 on a Rat Model of Parkinson's Disease Induced by 6-Hydroxydopamine
por: Wang, Jian Yu, et al.
Publicado: (2013)

Evaluation of the Association Between Serum Levels of Testosterone and Prolactin With 6- Hydroxydopamine-Induced Parkinsonism in Male Rats
por: Razaghi, Roghaieh, et al.
Publicado: (2021)

Lipid profiles in the cerebrospinal fluid of rats with 6-hydroxydopamine-induced lesions as a model of Parkinson’s disease
por: Qiu, Jiewen, et al.
Publicado: (2023)

Prosaposin PS18 reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of Parkinson’s disease
por: Wu, Kuo-Jen, et al.
Publicado: (2023)

The dosage of curcumin to alleviate movement symptoms in a 6-hydroxydopamine-induced Parkinson's disease rat model
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Pharmacological, Biochemical and Immunological Studies on Protective Effect of Mangiferin in 6-Hydroxydopamine (6-OHDA)-Induced Parkinson’s Disease in Rats
por: Tiwari, Prafulla Chandra, et al.
Publicado: (2021)

Lesioning of the Striatum Reverses Motor Asymmetry in the 6-Hydroxydopamine Rodent Model of Parkinsonism
por: Friehs, G. M., et al.
Publicado: (1991)

Upregulation of Cysteine Protease Cathepsin X in the 6-Hydroxydopamine Model of Parkinson’s Disease
por: Pišlar, Anja, et al.
Publicado: (2018)

Lipid Analysis of the 6-Hydroxydopamine-Treated SH-SY5Y Cell Model for Parkinson’s Disease
por: Xicoy, Helena, et al.
Publicado: (2019)

PNPLA6‐Related Disorder with Levodopa‐Responsive Parkinsonism
por: Kazanci, Serdar, et al.
Publicado: (2022)

Subtle Cardiovascular Dysfunction in the Unilateral 6-Hydroxydopamine-Lesioned Rat
por: Slack, K., et al.
Publicado: (2010)

Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
por: Shin, Keon Sung, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s2tsc7jcebusid3p44h55u8jp5